Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.42 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 6/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 6/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 6/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 5/20 | 0.39 |
| ▸ | LCK | P06239 | 5/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 5/20 | 0.39 |
| ▸ | MAP4K2 | Q12851 | 5/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.39 |
| ▸ | CLK2 | P49760 | 4/20 | 0.39 |
| ▸ | TAOK1 | Q7L7X3 | 4/20 | 0.39 |
| ▸ | PLK4 | O00444 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1901292 | 0.74 | MAP4K4 (0.53) | PIP4K2CMRGPRX1CSNK2A1IRAK4MAP4K4 | |
| SCHEMBL422306 | 0.74 | MRGPRX1 (0.47) | POLBLMNAGAAPKMPIP4K2C | |
| SCHEMBL16333140 | 0.72 | NPSR1 (0.67) | POLBCSNK2A2CSNK2BCSNK2A1NPSR1 | |
| SCHEMBL3343117 | 0.72 | LMNA (0.50) | POLBLMNAGAAPKMPIP4K2C | |
| SCHEMBL1902854 | 0.71 | ALDH1A1 (0.43) | POLBLMNAGAAPKMPIP4K2C | |
| SCHEMBL1905402 | 0.71 | MRGPRX1 (0.45) | POLBLMNAGAAPKMPIP4K2C | |
| SCHEMBL438061 | 0.71 | MAPT (0.53) | POLBLMNAGAAPKMPIP4K2C | |
| SCHEMBL10404544 | 0.70 | EGLN1 (0.40) | POLBMEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL1898735 | 0.70 | GABRP (0.40) | POLBLMNAGAAPKMPIP4K2C | |
| SCHEMBL13019361 | 0.68 | MRGPRX1 (0.43) | POLBLMNAGAAPKMPIP4K2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2320904-A2 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010030757-A2 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH2, HRH3 | POLB 2075/4885LMNA 4824/4885GAA 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.